Bonifacio M, Binotto G, Maino E, Calistri E, Marin L, Scaffidi L, Frison L, De Marchi F, Krampera M, Semenzato G, Fanin R, Ambrosetti A, Tiribelli M. Imatinib-treated chronic myeloid leukemia patients with discordant response between cytogenetic and molecular tests at 3 and 6 month time-points have a reduced probability of subsequent optimal response. Haematologica 2015; 100(8):e299-e301; https://doi.org/10.3324/haematol.2015.124685.